Holen Sie sich die Stockscreener-App
1.13
0.89%
0.010
Handel nachbörslich:
1.15
0.02
+1.77%
Enlivex Therapeutics Ltd Aktie (ENLV) Neueste Nachrichten
Sepsis Market Growth to Accelerate in Forecast Period - openPR.com
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle
Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel
Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus
Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus
Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times
Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan
Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal
Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times
Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud
Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times
ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus
Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com
Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus
Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView
Game-Changing Cell Therapy Helps Patients Avoid Knee Replacement: Clinical Trial Results Revealed - Stock Titan
Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo
Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at D. Boral Capital - Defense World
Enlivex (ENLV) Completes Patient Enrollment for Phase II Allocetra Trial | ENLV Stock News - GuruFocus
Enlivex Completes Phase II Enrollment for Osteoarthritis Trial - TipRanks
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - The Manila Times
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis | ENLV Stock News - GuruFocus
Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra - Stock Titan
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment - TipRanks
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need - Stock Titan
Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks
HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):